Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

PHRM 864 therapeutics > Lung Cancer Therapeutics > Flashcards

Lung Cancer Therapeutics Flashcards

1
Q

what are the 5 main mutations that can guide lung cancer therapy regimens

A

EGFR mutations
KRAS mutations
ALK inhibition
ROS-1 mutations
BRA V600E

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

what are the two main lung cancer groups

A

NSCLC
SCLC

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

describe SCLC

A

clear relationship to smoking
paraneoplastic syndromes common
rapid cell growth fraction
highly sensitive to radiation and chemotherapy

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

which lung cancer is highly sensitive to radiation and chemo

A

SCLC

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

what is a complication of therapy for SCLC

A

cisplatin complications (N/V, nephrotoxicity, ototoxicity, neuropathy
radiation complications

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

is surgery an option in SCLC

A

no

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

what is the intent in limited stage SCLC

A

curative intent

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

what is 1st line treatment for limited stage SCLC

A

combo chemo + radiation
cisplatin + etoposide w/ radiation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

is maintenance chemo an option for limited stage SCLC

A

no there is no benefit

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

what is the intent with extensive stage SCLC

A

not curative. prolong survival

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

what is the preferred treatment option in extensive SCLC

A

platinum based therapy w/o radiation
-cisplatin/carboplatin + etoposide/irinotecan

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

what is first line immunotherapy for extensive SCLC

A

carboplatin + etoposide + durvalumab OR atezolizumab

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

is maintenance chemotherapy acceptable in extensive SCLC

A

yes

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

what is a treatment option for metastatic SCLC patients who have progressed on or after platinum chemo and at least 1 prior line of therapy

A

pembrolizumab

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

how to treat relapse of extensive SCLC

A

> 6 months: original regimen +/- mab
<=6 months: topotecan, clinical trial, or pembrolizumab

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

what are the two main forms of NSCLC

A

adenocarcinoma (non-smokers)
squamous (smokers)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

what is the best treatment for NSCLC

A

surgery

18
Q

what is the treatment for resectable NSCLC

A
  1. surgery to remove
  2. adjuvant chemo based on histology
19
Q

what is the chemo regimen for resectable non-squamous NSCLC

A

cisplatin + premetrexed

20
Q

what is the chemo regimen for resectable squamous NSCLC

A

cisplatin + gemcitabine
cisplatin + docetaxel

21
Q

if a patient is unable to tolerate cisplatin, what can be substituted

A

carboplatin

22
Q

what is the treatment regimen for unresectable NSCLC

A

chemo + radiation + consolidation w/ mab

23
Q

what is the intent of treatment for unresectable NSCLC

A

stage IIIB/IV disease is palliative not curative

24
Q

for patients with unresectable NSCLC who are not candidates for surgery or chemo + radiation what is the preferred treatment option

A

pembrolizumab

25
Q

what is the chemo regimen for unresectable NSCLC

A

cisplatin + paclitaxel
cisplatin + gemcitabine
cisplatin + docetaxel

26
Q

what drug should be followed by chemo regimen and for how long

A

Durvalumab and for 12 months for maintenance/consolidation therapy

27
Q

what should be checked in all advance metastatic adenocarcinomas (non-squamous)

A

mutational status and PD-L1 status

28
Q

what is first line for metastatic adenocarcinomas with a positive mutation

A

TKIs first then immunotherapy

29
Q

what should be used with an EGFR + mutation (exon 19, exon 21, L858R mutation, T790M mutation)

A

Osimertinib

30
Q

what are side effects with Osimertinib

A

cardiomyopathy, RASH

31
Q

what should be used with a BRAF + mutation

A

Dabrafenib + Trametinib

32
Q

what are side effects of dabrafenib + trametinib

A

fevers, rash, visual changes, retinal detachment

33
Q

what should be used in K-RAS G12C mutation

A

Sotorasib
used after platinum based chemo +/- immunotherapy

34
Q

what is a side effect of Sotorasib

A

increased LFTs

35
Q

what is first line in metastatic adenocarcinoma with no mutation or oral chemo has been exhausted

A

Pembro or
Carbo + Pem ^2

36
Q

what is the treatment for mutation negative PD-L1 negative metastatic adenocarcinom

A

carboplatin + pemetrexed + pembrolizumab

37
Q

what is first line for metastatic squamous cell cancer

A

Pembrolizumab + Carboplatin + Paclitaxel

38
Q

what is the treatment for a patient with a CI to immunotherapy with metastatic squamous cell cancer

A

platinum doublet regardless of PD-L1 status

39
Q

what are the toxicities to immunotherapy

A

CHEN-P
Colitis
Hepatitis
Endocrine (thyroid/pituitary)
Nephritis
Pneumonitis

40
Q

what 6 labs should be monitored for patients receiving immunotherapy

A

CBC diff
CMP (renal, liver, glucose)
TSH and Free T4
Amylase and lipase

41
Q

who should consider lung cancer screening

A

patients at high risk
55-74 w/ 30 pack year of smoking and still in good health and willing to have curative surgery

PHRM 864 therapeutics (14 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2024 Bold Learning Solutions. Terms and Conditions